Medicare Coverage of Tumor Necrosis Factor α Inhibitors as an Influence on Physicians’ Prescribing Behavior
- 9 January 2006
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 166 (1) , 57-63
- https://doi.org/10.1001/archinte.166.1.57
Abstract
Research from JAMA Internal Medicine — Medicare Coverage of Tumor Necrosis Factor α Inhibitors as an Influence on Physicians’ Prescribing BehaviorThis publication has 17 references indexed in Scilit:
- Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort studyBMC Musculoskeletal Disorders, 2004
- Assessing the New Medicare Prescription Drug LawAnnals of Internal Medicine, 2004
- Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexateArthritis & Rheumatism, 2004
- Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapyArthritis & Rheumatism, 2004
- Who You Are And Where You Live: How Race And Geography Affect The Treatment Of Medicare BeneficiariesHealth Affairs, 2004
- Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003)Annals of the Rheumatic Diseases, 2003
- Medicare Breast Surgery Fees and Treatment Received by Older Women with Localized Breast CancerHealth Services Research, 2003
- Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomesArthritis & Rheumatism, 2002
- A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.PharmacoEconomics, 2001
- Physician response to fee changes with multiple payersJournal of Health Economics, 1991